Mid-regional pro-atrial natriuretic peptide as a biomarker of left ventricular systolic dysfunction in patients with sepsis

  • Trisulo Wasyanto Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sebelas Maret, Dr. Moewardi Hospital, Surakarta, Indonesia
  • Guntur Hermawan Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Dr. Moewardi Hospital, Surakarta, Indonesia
Keywords: biomarkers, left ventricular dysfunction, atrial natriuretic peptide, tumor necrosis factor-alpha
Abstract viewed: 639 times
PDF downloaded: 621 times
HTML downloaded: 119 times
EPUB downloaded: 251 times


BACKGROUND Releasing cytokine pro inflammation in patients with sepsis (tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β) and IL-6) with other factors (mid regional pro atrial natriuretic peptide [MR-proANP] and TNF-α) will cause left ventricular systolic dysfunction (LVSD). This research aimed to prove MR-proANP as a biomarker of LVSD in sepsis, area under the curve (AUC), sensitivity, specificity, cut-off point and probability of MR-proANP and TNF-α as a biomarker of LVSD.

METHODS Non-experimental diagnostic test with cross sectional design and simple random sampling. Variable examined consisted of MR pro ANP, TNF-α and left ventricular ejection fraction (LVEF). LVSD if LVEF was ≤45%. Statistical analysis using 2 x 2 table and receiver operating characteristic curve using SPSS 22 for window.

RESULTS There were examined 71 patients from November 2013 to March 2014 in tertiary ICU of Moewardi Hospital. There were 22 patients with mild sepsis (30.9%), 40 patients with severe sepsis (56.4%) and 9 patients with septic shock (12.7%). The AUC value of MR-proANP level was 0.84 (95% CI 0.73-0.95), p < 0.001. Optimal cut off point was ≥225.95 pmol/l and diagnostic odd ratio (DOR) was 12.11. The AUC value of TNF-α level was 0.73 (95% CI 0.60-0.86), p < 0.002. Optimal cut-off point was ≥7.36 pg/ml and DOR was 5.03. Multivariate analysis was resulted that MR-proANP was the best predictor of LVSD (AUC 0.78), and TNF-α (0.69).

CONCLUSIONS MR-proANP could be used as a biomarker and the best diagnostic predictor of LVSD.


  1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327. https://doi.org/10.1097/01.CCM.0000298158.12101.41

  2. Flierl MA, Rittirsch D, Huber-Lang MS, Sarma JV, Ward PA. Molecular events in the cardiomyopathy of sepsis. Mol Med. 2008;14(5-6):327-36. https://doi.org/10.2119/2007-00130.Flierl

  3. Fernandes CJ Jr, de Assuncao MS. Myocardial dysfunction in sepsis: a large, unsolved puzzle. Crit Care Res Pract. 2012;2012:896430. https://doi.org/10.1155/2012/896430

  4. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarker of sepsis in critical care. J Antimicrob Chemother. 2011;66(Suppl 2):ii33-40. https://doi.org/10.1093/jac/dkq523

  5. Ladetzki-Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A, et al. Atrial natriuretic peptide, a regulator of nuclear factor κB activation in vivo. Endocrinology. 2007;148(1):332-6. https://doi.org/10.1210/en.2006-0935

  6. Kiemer AK, Vollmar AM. The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis. 2001;60(Suppl 3):iii68-70.

  7. Lipinska-Gediga M, Mierzchala M, Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection. 2012;40(3):303-9. https://doi.org/10.1007/s15010-011-0235-0

  8. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care. 2005;9(1):R37-45. https://doi.org/10.1186/cc3015

  9. Celes MR, Prado CM, Rossi MA. Sepsis: going to the heart of the matter. Pathobiology. 2013;80(2):70-86. https://doi.org/10.1159/000341640

  10. de Backer D, Cholley BP, Slama M, Vieillard-Baron A, Vignon P. Hemodynamic Monitoring Using Echocardiography in the Critically Ill. Septic Shock 2011. https://doi.org/10.1007/978-3-540-87956-5

  11. Jozwiak M, Persichini R, Monnet X, Teboul JL. Management of myocardial dysfunction in severe sepsis. Semin Respir Crit Care Med. 2011;32(2):206-14. https://doi.org/10.1055/s-0031-1275533

  12. Zanotti Cavazzoni SL, Guglielmi M, Parrillo JE, Walker T, Dellinger RP, Hollenberg SM. Ventricular dilation is associated with improved cardiovascular performance and survival in sepsis. Chest. 2010;138(4):848-55. https://doi.org/10.1378/chest.09-1086

  13. Griffee MJ, Merkel MJ, Wei KS. The role of echocardiography in hemodynamic assessment of septic shock. Crit Care Clin. 2010;26(2):365-82. https://doi.org/10.1016/j.ccc.2010.01.001

  14. Oliver JC, Bland LA, Oettinger CW, Arduino MJ, McAllister SK, Aguero SM, et al. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res. 1993;12(2):115-20.

How to Cite
Wasyanto T, Hermawan G. Mid-regional pro-atrial natriuretic peptide as a biomarker of left ventricular systolic dysfunction in patients with sepsis. Med J Indones [Internet]. 2019Aug.9 [cited 2023Jun.3];28(2):129-33. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/1952
Clinical Research